Evidence map›Paper›PMID 31454426›Full record

ArticleCancer2019

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.

Maeve A Lowery, Laura W Goff, Bridget P Keenan, Emmet Jordan, Rui Wang, Andrea G Bocobo, Joanne F Chou, Eileen M O'Reilly, James J Harding, Nancy Kemeny and 6 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Maeve A LoweryMemorial Sloan Kettering Cancer Center, New York, New York.
Laura W GoffVanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Bridget P KeenanHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Emmet JordanMemorial Sloan Kettering Cancer Center, New York, New York.
Rui WangMemorial Sloan Kettering Cancer Center, New York, New York.
Andrea G BocoboHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Joanne F ChouMemorial Sloan Kettering Cancer Center, New York, New York.
Eileen M O'ReillyMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-8076-9199
James J HardingMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-7029-4310
Nancy KemenyMemorial Sloan Kettering Cancer Center, New York, New York.
Marianela CapanuMemorial Sloan Kettering Cancer Center, New York, New York.
Ann C GriffinHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Joseph McGuireHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Alan P VenookHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Ghassan K Abou-AlfaMemorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-1522-8054
Robin K KelleyHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.ORCID https://orcid.org/0000-0002-1984-2430
Memorial Sloan Kettering Cancer Center · USUniversity of California, San Francisco · USVanderbilt University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0M
Cholangiocarcinoma FoundationNCI NIH HHS P30 CA008748NIAID NIH HHS T32 AI007334
6 · The paper itself

Abstract

backgroundAlthough gemcitabine plus platinum chemotherapy is the established first-line regimen for advanced biliary cancer (ABC), there is no standard second-line therapy. This study evaluated current practice and outcomes for second-line chemotherapy in patients with ABC across 3 US academic medical centers.

methodsInstitutional registries were reviewed to identify patients who had received second-line chemotherapy for ABC from April 2010 to March 2015 along with their demographics, diagnoses and staging, treatment histories, and clinical outcomes. Overall survival from the initiation of second-line chemotherapy (OS2) was estimated with Kaplan-Meier methods.

resultsThis study identified 198 patients with cholangiocarcinoma (intrahepatic [61.1%] or extrahepatic [14.1%]) or gallbladder carcinoma (24.8%); 52% received at least 3 lines of systemic chemotherapy. The median OS2 was 11 months (95% confidence interval [CI], 8.8-13.1 months). The median OS2 for patients with intrahepatic cholangiocarcinoma was 13.4 months (95% CI, 10.7-17.8 months), which was longer than that for patients with extrahepatic cholangiocarcinoma (6.8 months; 95% CI, 5-10.6 months) or gallbladder carcinoma (9.4 months; 95% CI, 7.2-12.3 months; P = .018). The median time to second-line treatment failure was 2.2 months (95% CI, 1.8-2.7 months), and it was similar across tumor locations (P = .60).

conclusionsIn this large cohort of patients with ABC treated across 3 academic medical centers after the failure of first-line chemotherapy, the time to treatment failure on standard therapies was short, although the median OS2 was longer than has been reported previously, and more than half of the patients received additional lines of treatment. This multicenter collaboration represents the largest cohort studied to date of second-line chemotherapy for ABC and provides a contemporary benchmark for future clinical trials.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingRetreatmentRetrospective StudiesTreatment FailureTreatment Outcomebile duct cancerbiliary cancerchemotherapycholangiocarcinomagallbladder cancersecond line

Identifiers

PMID31454426
PMCPMC8172082
OpenAlexW2970687130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.